Cargando…
Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991202/ http://dx.doi.org/10.1186/2051-1426-1-S1-P26 |
| _version_ | 1782312394084581376 |
|---|---|
| author | Opel, Cary F Wittrup, K Dane |
| author_facet | Opel, Cary F Wittrup, K Dane |
| author_sort | Opel, Cary F |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3991202 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39912022014-05-05 Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival Opel, Cary F Wittrup, K Dane J Immunother Cancer Poster Presentation BioMed Central 2013-11-07 /pmc/articles/PMC3991202/ http://dx.doi.org/10.1186/2051-1426-1-S1-P26 Text en Copyright © 2013 Opel and Wittrup; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Opel, Cary F Wittrup, K Dane Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival |
| title | Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival |
| title_full | Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival |
| title_fullStr | Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival |
| title_full_unstemmed | Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival |
| title_short | Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival |
| title_sort | combined treatment using adoptive cell therapy, extended pharmacokinetic il-2, and tumor-specific antibodies leads to cures of established b16f10 tumors and extended in vivo t cell survival |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991202/ http://dx.doi.org/10.1186/2051-1426-1-S1-P26 |
| work_keys_str_mv | AT opelcaryf combinedtreatmentusingadoptivecelltherapyextendedpharmacokineticil2andtumorspecificantibodiesleadstocuresofestablishedb16f10tumorsandextendedinvivotcellsurvival AT wittrupkdane combinedtreatmentusingadoptivecelltherapyextendedpharmacokineticil2andtumorspecificantibodiesleadstocuresofestablishedb16f10tumorsandextendedinvivotcellsurvival |